Promising antibody development for breast cancer treatment
In a step towards advancing breast cancer treatment, researchers have pioneered a novel monoclonal antibody which specifically targets a certain type of breast cancer cell. This development offers a new tool to enhance the efficacy of treatment while also presenting an avenue for reducing the incidence and severity of side effects experienced by breast cancer patients.
In the study, published in the open access International Journal of Molecular Sciences, researchers from Tohoku University developed a monoclonal antibody, named H2Mab-250, that precisely targets HER2-positive breast cancer cells. The primary objective of their research was to assess the efficiency of monoclonal antibodies in selectively targeting HER2-positive breast cancer cells while sparing adjacent healthy cells form harm.
HER2-positive breast cancer emerges as one of the most aggressive and challenging subtypes to manage. These cells showcase an abundance of the HER2 protein on their surface, exceeding levels observed in healthy cells. Integral to the regulation of cell growth and division, the HER2 protein assumes a pivotal role. Its heightened presence significantly drives the aggressiveness of HER2-positive tumours.
According to the Breast Cancer Research Foundation, around 20 percent of breast cancer cases fall under the category of HER2-positive. This underscores the critical necessity for therapies tailored to address this specific subtype. However, a notable concern associated with this approach is the potential for treatment to inadvertently harm healthy cells that express similar molecules.
In response to these challenges, the researchers developed the monoclonal antibody, H2Mab-250, with the precise aim of targeting HER2-positive cells. This antibody works to disrupt the growth and proliferation of these cells while simultaneously minimising damage to surrounding healthy tissue.
"The development of this antibody represents a significant milestone in our ongoing efforts to advance breast cancer treatment," says author on the paper, Yukinari Kato. "By targeting HER2-positive breast cancer cells with precision, we can offer patients a more effective and less toxic treatment option."
What sets this development apart is the antibody's ability to provide a more targeted and selective approach compared to traditional treatments like chemotherapy. Unlike chemotherapy, which often leads to considerable collateral damage to nearby healthy cells, this innovative antibody specifically zeros in on the intended targets, minimising damage to surrounding healthy tissue.
In the study, the researchers conducted tests on the monoclonal antibody to evaluate its interaction with both breast cancer cells and normal cells. Contrasting it with trastuzumab, a clinically approved anti-HER2 antibody, they found that their monoclonal antibody, H2Mab-250, selectively targeted HER2-positive breast cancer cells, while trastuzumab showed reactivity to both breast cancer and normal epithelial cells. By precisely focusing on HER2-positive cells, the monoclonal antibody effectively hindered the growth and division of cancerous cells while also minimising harm to nearby healthy tissue.
These findings indicate that the novel monoclonal antibody holds promise for the development of new cancer treatments, potentially offering a safer and more effective option for breast cancer therapy.
The project is set to advance to the next phase, which will include clinical trials. In addition, the researchers will also investigate potential applications of other novel antibodies in various therapeutic domains, aiming to enhance outcomes for people living with different forms of cancer.
If you're interested in learning more about this research, you can access the paper published in the International Journal of Molecular Sciences here: https://shorturl.at/wzHU2